Country
Clinical Trials in Luxembourg
Studies with at least one site in Luxembourg. Open a trial for its sites in Luxembourg, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 24Parkinson's Disease
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene.
- Trial name
- PreCoDe (NCT07055087)
- Testing
- Prasinezumab, Sodium Chloride
- Where
- 11 sites in France, Germany and 5 more
- Volunteers
- 120 people
- Sponsor
- University Hospital Tuebingen
Bradyarrhythmias, AV Block Complete
Belgo-Luxembourg Leadless PM Registry
This is a single-arm, multicenter clinical study evaluating the long-term effectiveness and safety profile of the CE-marked and commercially available Aveir leadless pacemaker systems manufactured by Abbott.
- Conditions
- Bradyarrhythmias, AV Block Complete, AV Block-2Nd Degree-Type 1, Pacemaker
- Trial name
- BELLA (NCT07879716)
- Testing
- CT scan heart, 24 hour ambulatory ECG monitoring
- Where
- 9 sites in Belgium, Luxembourg
- Volunteers
- 190 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Stroke, Hemiparesis
Quadriceps Muscle Activity and Gait Kinematics in Patients With Post-Stroke Stiff-Knee Gait Compared With Healthy Controls
Stiff-knee gait (SKG) is a frequent gait abnormality in people with post-stroke hemiparesis and is characterized by insufficient knee flexion during the swing phase of walking.
- Trial name
- FW QUADRI (NCT07857967)
- Where
- Luxembourg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Frédéric Chantraine
Any Condition
VOCAL BIOMARKERS FOR HEALTH MONITORING: AN OPEN LONGITUDINAL HYBRID COHORT STUDY
Voice could be considered a new vital sign in the future, being collected in routine care and complement other medical assessments. Vocal biomarkers (VB) are voice characteristics that are specific to a disease or symptom.
- Trial name
- SONAR (NCT07665229)
- Where
- Luxembourg
- Volunteers
- 3,700 people, healthy volunteers welcome
- Sponsor
- Luxembourg Institute of Health
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
The Clinnova-Multiple Sclerosis (MS) study is part of the Clinnova program (NCT06526364; NCT06235684 and NCT05733702), which seeks to advance precision medicine and the digitalization of healthcare through high-quality…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive, Clinically Isolated Syndrome, Primary Progressive Multiple Sclerosis
- Trial name
- Clinnova-MS (NCT07280871)
- Testing
- Cohort
- Where
- Luxembourg
- Volunteers
- 100 people
- Sponsor
- Luxembourg Institute of Health
Colorectal Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC
The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform in colorectal cancer and pancreatic ductal adenocarcinoma patients.
- Trial name
- COLOPan (NCT07500259)
- Testing
- Personalized Functional Profiling
- Where
- Luxembourg
- Volunteers
- 188 people
- Sponsor
- Luxembourg Institute of Health
Long COVID
Development of Voice Biomarkers of Frequent COVID-19 and Long Covid-related Symptoms Based on Data From Users of the Long COVID Companion App
The LIH DDP research team focuses its research topics on vocal biomarkers and Long COVID, among others. Voice is indeed a promising tool to monitor health, as it contains many information on our health and is easy to collect.
- Trial name
- EVO-LC (NCT07156994)
- Testing
- No Intervention: Observational Cohort
- Where
- Luxembourg
- Volunteers
- 300 people
- Sponsor
- Luxembourg Institute of Health
Chronic Disease
Identification of Vocal Biomarkers to Monitor the Health of People With a Chronic Disease
The CoLive Voice research project aims to identify vocal biomarkers of severe conditions and frequent health symptoms. The project is based on digital technologies and statistical algorithms.
- Trial name
- CoLive Voice (NCT04848623)
- Where
- Luxembourg
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Luxembourg Institute of Health
Parkinson Disease
Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen…
- Trial name
- LuxPARK (NCT05266872)
- Testing
- Observational study with sample and data collection
- Where
- 2 sites in Luxembourg
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Luxembourg Institute of Health
Metastatic Breast Cancer
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type…
- Trial name
- AURORA (NCT02102165)
- Testing
- metastatic lesion biopsy
- Where
- 52 sites in Belgium, Germany and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Jules Bordet Institute
Completed, with results posted
All 31Distal Radius Fractures
Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.
Prospective, single arm, monocentric clinical study to test NVDX3 in patients suffering from distal radius fracture. NVDX3 will be implanted during a single surgical intervention.
- Trial name
- NCT05987033
- Testing
- NVDX3
- Where
- Luxembourg
- Volunteers
- 11 people
- Sponsor
- Novadip Biosciences
Diabetic Foot Ulcer
Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers
The purpose of this study is to evaluate the efficacy, safety and economical benefits of Cyclical Pressure Topical Wound Oxygen (TWO2) Therapy in the treatment of chronic diabetic foot ulcers.
- Trial name
- TWO2DFU (NCT02326337)
- Testing
- TWO2 Device
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 73 people
- Sponsor
- AOTI Ltd.
Metastatic Castration-resistant Prostate Cancer
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing…
- Trial name
- REASSURE (NCT02141438)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Argentina and 18 more
- Volunteers
- 1,472 people
- Sponsor
- Bayer
Type 1 Diabetes Mellitus
The Artificial Pancreas in Very Young Children With T1D
The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme and JDRF.
- Trial name
- KidsAP02 (NCT03784027)
- Testing
- CamAPS FX, Sensor augmented therapy
- Where
- 8 sites in Austria, Germany and 2 more
- Volunteers
- 81 people
- Sponsor
- University of Cambridge
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent…
- Trial name
- IPSOS (NCT03191786)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Vinorelbine, Gemcitabine
- Where
- 91 sites in Argentina, Belgium and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche